Liquid-based cytology technologies, such as the ThinPrep Pap Test (Cytyc, Boxborough, MA) and Autocyte PREP thin-layer (TriPath Imaging, Burlington, NC), increasingly are used in cervical cancer screening programs throughout the developed world. Previous studies suggested that the benefits of these technologies include same-cervical scraping for cytology and virus testing, 1-12 increased sensitivity for the detection of preneoplastic precursors, 13-26 thereby theoretically decreasing the risk of dying of cervical cancer, and improved adequacy of sampling. [14] [15] [16] 18, 20, 21, 23, 27 Arguments that the risk of dying of cervical cancer mainly lies in the unscreened population (a population untouched by the introduction of these new technologies) are largely ignored, 28 as screening programs increasingly are switching from conventional to liquid-based preparations.
A b s t r a c t

The amount of money a woman is willing to pay for liquid-based cytology technology has not been measured. In the present study, 175 women answered a questionnaire asking how much they would pay to decrease their risk of dying of cervical cancer if a new (liquid-based) Papanicolaou (Pap) test was used in
Liquid-based cytology technologies, such as the ThinPrep Pap Test (Cytyc, Boxborough, MA) and Autocyte PREP thin-layer (TriPath Imaging, Burlington, NC), increasingly are used in cervical cancer screening programs throughout the developed world. Previous studies suggested that the benefits of these technologies include same-cervical scraping for cytology and virus testing, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] increased sensitivity for the detection of preneoplastic precursors, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] thereby theoretically decreasing the risk of dying of cervical cancer, and improved adequacy of sampling. [14] [15] [16] 18, 20, 21, 23, 27 Arguments that the risk of dying of cervical cancer mainly lies in the unscreened population (a population untouched by the introduction of these new technologies) are largely ignored, 28 as screening programs increasingly are switching from conventional to liquid-based preparations.
The potential negative aspect of liquid-based technologies is the added cost that generally is absorbed by third-party payers. Conclusions about the cost-effectiveness of these new cytology technologies have been conflicting, 16, [28] [29] [30] [31] [32] [33] [34] [35] especially when compared with conventional screening on a yearly basis, the frequency of screening advocated by most American physicians. Assuming an additional cost per liquid-based cytology test of $10 and 250 million screenings per year, if used for every screening encounter, the added annual cost in the United States would be in the range of $2.5 billion. 30 An alternative way to study the economic utility of liquid-based technologies is to perform a willingness-to-pay or contingent valuation survey. [36] [37] [38] Olsen and Smith 36 reported several advantages of using the metric of willingness to pay instead of the metric of quality-adjusted life year that commonly is used in cost-effectiveness studies. In theory, willingness to pay is based on individual preference and welfare economics; responses are evaluated that are contingent on hypothetical markets. Previous health care willingness-to-pay studies have focused on subjects' willingness to pay for therapeutic interventions [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] or health care programs, 51, 52 in which the potential beneficial net outcomes are directly perceived by subjects as an improvement in their health. Few studies have measured willingness to pay for diagnostic testing, 53, 54 in which the potential benefits are not directly perceived by the subject. No previous willingnessto-pay study has examined subjects' willingness to pay for anatomic pathology diagnostic testing. For cervicovaginal screening, contingent valuation involves asking subjects the maximum sum of money they are willing to pay to have the commodity in question (liquid-based cytology technology).
We attempted to determine whether the costs used in the liquid-based technology cost-effectiveness studies were similar to the costs American women were willing to pay. Factors that influence willingness to pay were evaluated to determine whether different subgroups of women were more or less willing to pay for liquid-based technologies.
Materials and Methods
Approval for the study was obtained from the institutional review board at Allegheny General Hospital, Pittsburgh, PA.
Study Subjects
The study subjects consisted of a convenience sample of 175 female patients who attended an office visit at 1 of 3 obstetric-gynecology practices associated with Allegheny General Hospital between November 1, 2000, and January 31, 2000. While in the waiting room, patients were approached by one of us (A.R.H.) and offered participation in a voluntary, anonymous survey. Participants were not compensated. Approximately 40% of persons queried agreed to participate in the survey. After informed consent to participate was obtained, the questionnaire was administered to each participant on a face-to-face basis. Although a copy of the questionnaire was provided to each participant, the survey administrator read aloud the introduction and each of the questions and recorded the responses. On average, the questionnaire took 20 to 30 minutes to administer.
Questionnaire
The willingness-to-pay questionnaire was developed in the Department of Pathology and Laboratory Medicine in conjunction with the Department of Performance Improvement at Allegheny General Hospital. The questionnaire was designed to elicit willingness to pay for new Pap test (liquidbased) technologies using a payment card questionnaire format. In health care willingness-to-pay studies, this format has been the most frequently used. 37, 38, 55 Payment cards present a series of dollar amounts to respondents, in an incremental list from $0 to the highest amount. Respondents are asked to indicate the most they would pay for the therapy, program, test, or other variable. This questionnaire was composed of 3 parts: (1) introduction, (2) contingent valuation questions, and (3) demographic and other questions relating to the participant's experience with Pap tests. Demographic and previous Pap test experience questions were presented at the end to maximize the response rate. 50 The questionnaire was pilot-tested on 17 female staff at Allegheny General Hospital to assess the length of time for completion, the clarity of the presented information and questions, and the appropriateness of the contingent valuation payment card range. The pilot test participants were cytotechnologists, nurses, physicians, information systems personnel, and medical transcriptionists. The payment card range was adjusted as a result of the pilot testing.
The questionnaire introduction provided information about conventional Pap smear screening, the impact of Pap smear screening on decreasing the risk of dying of cervical cancer in the United States, the current average risk of dying of cervical cancer in Pennsylvania, [56] [57] [58] new Pap tests and their potential benefits, 13 charges for conventional and liquid-based Pap tests, and the risks for an average American of dying of a variety of other causes (eg, particular diseases, accidents, natural disasters). 57, 59, 60 The specific new testing method used as an example was the ThinPrep Pap Test.
The contingent valuation questions were posed in the context of 4 different scenarios. The first scenario asked the participant to indicate her willingness to pay out-of-pocket for the new Pap test, assuming that her risk of dying of cervical cancer was the same as the average risk for a woman living in Pennsylvania and screened regularly (1 in 37,000). [56] [57] [58] This scenario measured the ex ante perspective; the respondents did not know their personal risk but only the average risk for the population to which they presumably belonged. The participant was able to compare this average risk with the risks of dying of other causes (presented in the introduction). Each contingent valuation payment card presented a range of $0 to $1,000, with 9 intervening values. Participant willingness to pay out-of-pocket was elicited for 4 different new Pap test performance levels, represented by 4 different risk-reduction levels for dying of cervical cancer. Specifically, participant willingness to pay out-of-pocket was elicited for the following risk levels: by having the new Pap test, the risk of dying of cervical cancer was reduced from 1:37,000 to (1) 1:50,000, (2) 1:100,000, (3) 1:1,000,000, and (4) 0 (she definitely would not die of cervical cancer). In actuality, it has not been shown that the new Pap test confers a decreased risk of dying of cervical cancer, but only an increased detection of preneoplastic lesions. However, it was © American Society for Clinical Pathology assumed in all contingent valuation scenarios that the increased sensitivity of the new Pap test could lead to different outcomes (slightly, moderately, or markedly reduced risk of dying of cervical cancer). The respondents were not asked about their willingness to pay for increased detection of preneoplastic lesions.
The second scenario asked the participant her willingness to pay out-of-pocket for the new Pap test assuming that her risk of dying of cervical cancer was greater than the Pennsylvania average (baseline risk increased from 1:37,000 to 1:10,000). This scenario measured the ex post perspective (ie, it assumed that the respondents knew they were at high risk). The contingent valuation payment cards and new Pap test performance levels were exactly the same as described for the first scenario.
The third scenario asked the participant her willingness to pay for a public program that would provide the new Pap test for all Pennsylvanians; this program would be funded through higher taxes. It has been suggested that willingnessto-pay questions should be asked in the form of hypothetical insurance purchasing or other public funding methods, because participants typically do not pay for diagnostic tests at the point of care. 61, 62 This scenario also explored the altruistic willingness to pay. The respondents were told that 241 Pennsylvanians die per year of cervical cancer, and approximately 6.2 million women live in Pennsylvania. [56] [57] [58] The respondents were presented with the same payment card for 4 different new Pap test performance levels, represented by differences in death rate reduction. Specifically, participant willingness to pay for a public program was elicited for the following annual reductions in cervical cancer deaths attributed to the new Pap test: (1) 241, (2) 121, (3) 91, or (4) 51.
The fourth scenario explored the willingness to trade off 2 risks (decreased risk of cervical cancer death vs decreased risk of infertility [eg, increasing the risk of live births]) rather than to trade off 1 risk for dollars. It has been suggested that responses to risk-risk trade-off questions may be more stable than responses to risk-dollar trade-offs. 50 This scenario asked the respondent to imagine that Pennsylvania was holding a referendum on 2 alternative uses of public funds; 1 would provide new Pap test coverage for all state residents and the other would provide coverage for an in vitro fertilization (IVF) program for state couples who were infertile. IVF previously has been studied using contingent valuation. 50 Respondents were told that the new Pap test program would result in an annual decrease in the number of cervical cancer deaths from 241 to 121. Respondents were asked to choose their program preference (new Pap test program or IVF program) assuming varying numbers of new births per year (1, 50, 100, 500, 1,000, and 5,000) made possible by the IVF program.
The third part of the questionnaire contained 6 demographic items and 5 items relating to the respondent's previous experience with Pap tests: (1) 
Statistical Analysis
Descriptive statistics were used to summarize responses to the willingness-to-pay, demographic, and Pap test experience questions. Relationships between demographic and Pap test experience independent variables were examined using the Pearson and the Spearman rank correlation coefficients.
In willingness-to-pay studies, a positive relationship between willingness to pay and ability to pay, as measured by household income, generally exists. 50 This relationship is predicted by economic theory, and this association often is used as a check for the internal validity of the survey. To test the internal validity for the first 3 scenarios, the mean and median willingness-to-pay values were tested for positive correlation with household income as a categoric variable using the Pearson correlation coefficient. Correlation analysis also was performed with household income as a dichotomous variable falling above or below the median income.
As a test of construct validity, willingness to pay should increase as the degree of perceived benefits increases. For example, willingness to pay values for the ex ante (lower risk) and ex post (higher risk) perspectives were compared to determine whether women were willing to pay more for the ex post perspective, because, presumably, the new Pap test yielded greater benefit in this scenario. In addition, willingness-to-pay values were compared with the various performances of the new Pap test (assuming a greater benefit if the reduction in risk of death was greater), with actual and perceived risks for developing cervical cancer (assuming a greater benefit if the actual or perceived risk was higher), and with the perceived benefit of conventional Pap smear screening (assuming a perception of greater benefit if women received frequent screening). Relationships between these independent variables and the willingness-to-pay values were examined using the Pearson and the Spearman rank correlation coefficients and chi-square tests. Differences in mean willingness-to-pay values were examined using the Student t test.
Multivariate regression analysis was used to determine which independent variables predicted willingness to pay. In addition to the independent variables discussed in the preceding text, marital status, number of children, and highest education level were included in the model. Because willingness to pay was not normally distributed, a log-transformed model was compared with the non-log-transformed model. Statistically significant associations between demographic and previous Pap test experience variables or risk trade-off (decreased risk of dying of cervical cancer and increased risk of live births) were examined using a chi-square test.
All statistical analyses were performed using the statistical software program SPSS (9.0; SPSS, Chicago, IL), and statistical significance was assumed at P = 0.05 or less.
Results
Respondents
Respondent demographic characteristics and previous
Although a statistically significant correlation between annual household income and insurance coverage for Pap tests did not exist, a tendency was seen for respondents with higher annual household incomes to have insurance coverage. A statistically significant association was seen between having a previous abnormal Pap test result and having a perception of being at high risk for cervical cancer.
Respondent Willingness to Pay
A summary of the mean and median willingness to pay values and the choice between a Pap test program and an IVF program are shown in ❚Table 3❚.
Internal Validity
No statistically significant correlation between household income and willingness to pay was seen for any of the contingent valuation scenarios. Because respondents with higher incomes also tended to have insurance coverage for Pap tests, we examined the willingness to pay of respondents by insurance coverage. No statistically significant difference in the mean willingness to pay between respondents with insurance coverage for Pap tests and those without coverage was seen. However, a tendency for respondents with coverage to report a lower willingness to pay was seen; the median willingness to pay out-of-pocket for the ex ante scenario (scenario 1) for those without coverage was $275 compared with a median of $50 for those with coverage ❚Figure 1❚. Previous willingnessto-pay studies have shown that persons paying premiums for health insurance coverage come to expect new technologies to be covered by their insurance plans and, therefore, report a lower willingness to pay. 53 
Construct Validity
A summary of the mean and median willingness to pay for the ex ante perspective (scenario 1) and the ex post perspective (scenario 2) is shown in ❚Figure 2❚. No statistically No statistically significant differences were seen in the mean willingness to pay at different new Pap test performance levels. However, a tendency was observed for willingness to pay to increase as the performance level of the new Pap test increased.
A tendency was observed for respondents with a history of an abnormal Pap test to report a higher willingness to pay compared with those without a history of an abnormal Pap test, although the means were not statistically different. A tendency also was seen for respondents who perceived themselves to be at high risk for developing cervical cancer to have a greater willingness to pay compared with those who did not perceive themselves to be at high risk. This trend is shown in ❚Figure 3❚ for the ex ante and ex post scenarios and the public funding scenario (scenario 3), at the lowest performance levels of the new Pap test.
Predictors of Willingness to Pay
❚Table 4❚ summarizes the results of the regression analyses using the willingness to pay for the new Pap test at its highest performance level (no risk of dying of cervical cancer). All statistically significant covariate predictors of willingness to pay were positive predictors. The overall explanatory power of the ex ante (scenario 1) and ex post (scenario 2) regressions measured as R 2 were 0.363 and 0.484, respectively, for the non-log-transformed model. The overall explanatory power of the ex ante (scenario 1) and ex post (scenario 2) regressions measured as R 2 were 0.277 and 0.295, respectively, for the log-transformed model. Results were similar for regressions at lower Pap test performance levels. The regression analysis for the public funding scenario (scenario 3) yielded no statistically significant covariate predictors of willingness to pay. The mean willingness to pay was higher for respondents with more than 2 children compared with those with 2 or fewer children (P = .038). ❚Figure 4❚ shows the mean and median willingness to pay by number of children for the ex post scenario (scenario 2).
By using chi-square analysis for scenario 4, statistically significant associations were found between the choices of publicly funded programs (Pap test or IVF) and marital status (P = .049; married women were less likely to choose the IVF program) and education level (P = .023, less educated women were more likely to choose the IVF program).
Discussion
These data show that most women were willing to pay $50 to $100 per year to decrease their risk of dying of cervical cancer by small amounts. Some women were willing to pay significantly more. Even the median amounts women were willing to pay for liquid-based technologies (dollars they would spend in addition to their insurance coverage for conventional screening) are higher than the current laboratory reimbursement for conventional Pap smears (in most geographic locations). From a laboratory perspective, these data indicate that the conventional and liquid-based Pap tests are undervalued.
There are several reasons why liquid-based cytology technologies increasingly are being used in the American marketplace. For one, these technologies reportedly are more sensitive than the conventional smear, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] although increased Pap test sensitivity has never been proved to increase life expectancy, particularly in regular screening programs. Thus, in this study, the assumption that new Pap tests would increase life expectancy (even minutely) may not be valid. However, cost-effectiveness analyses of cervical cancer screening have assumed that sensitivity is the most important measure and that life expectancy is the most important outcome of analysis. [29] [30] [31] [32] [33] Our data showed that women were willing to pay considerably more than the dollar amounts assumed in these analyses. [29] [30] [31] [32] [33] Assuming a 30-year-old woman was willing to pay $50 extra per year for a liquidbased technology, that woman would pay more than $12,000 (assuming inflation) out-of-pocket during 40 years if she lived to be 70 years old.
It is interesting to note that women were willing to pay for the new Pap test, even though their risk of dying of cervical cancer was an extremely uncommon event with routine conventional Pap smear screening. Thus, it would seem that most women were risk-averse to maintaining a current screening system if something potentially more beneficial was available. One could hypothesize that other improvements in cervical cancer screening (eg, human papillomavirus testing or automated rescreening methods) would be desirable if they also resulted in increased Pap test sensitivity.
It is important to view this study as a pilot study. Contingent valuation methods are susceptible to a number of biases. 55 For example, range or "anchoring" bias may occur if respondents are influenced by the range of values presented to them when using a payment card approach. Neumann and Johannesson 50 demonstrated the presence of range bias when using a payment card approach to measure willingness to pay for IVF. When a subset of respondents in that study were presented with a range that was double that given to the main study sample, the subset respondents reported an average willingness to pay of 30% more. 50 We did not test for range bias in our respondents. One way to avoid range bias completely is to use a different questionnaire format, the binary approach, in which each respondent accepts or rejects a single bid. 49, 55 Strategic or "play money" bias occurs when questionnaire respondents inflate their willingness to pay to "game" the process or because they know no money will actually be collected from them. 50, 55 It has been suggested that binary approaches to contingent valuation measurement make it more difficult for any one individual, who may exhibit strategic bias, to have a significant effect on overall willingness to pay. 55 However, others have reported that the contingent valuation questionnaire format is affected by strategic bias for public, not private, goods. 63 The frame of our questionnaire placed an emphasis on life expectancy rather than on the detection of preneoplastic lesions (which is the actual benefit of liquid-based technologies), and this bias may have resulted in higher willingnessto-pay responses. Another potential bias in the study frame was that women were provided only the opportunity to purchase one type of technology. We did not provide women the option of purchasing a list of technologies (eg, improved mammograms) in addition to liquid-based technology. With limited resources, women may have been willing to pay less LG, log-transformed model; NT, non-log-transformed model. * For descriptions of the ex ante and ex post perspectives, see the "Questionnaire" section in "Materials and Methods." Highest education level: women with more education were willing to pay more money; number of children: women with more children were willing to pay more money; marital status: single women were willing to pay more money; age: older women were willing to pay more money; age at first Pap test: older women were willing to pay more money. for liquid-based technology if they also had the option of purchasing other technologies. The sample used in this study was not representative of all Pennsylvanians; the sample was made up exclusively of women, and the education and income level were above that of the general population. 64 Although one would expect an association between willingness and ability to pay, previous studies have suggested that an inability to demonstrate such a statistically significant association may be explained by various and potentially subtle factors. 52 For example, preferences of respondents in lower income groups may be different from those in higher income groups. Lower income respondents also might be willing to pay more if they could acquire a loan; Narbro and Sjostrom 47 reported that more than 50% of the respondents in their study of willingness to pay for obesity treatment deemed it necessary to borrow money to cover their willingness to pay. In that study, patients who required a loan had lower household incomes but were willing to pay twice the amount compared with patients who did not need a loan. In our study, it is possible that some of the lower income respondents assumed that they could borrow money. The maximum yearly income category we analyzed was $50,000 or more, which contained more than one third of the respondents; further stratifying income at higher levels could have led to the demonstration of a statistically significant association. It also is possible that many of the dollar amounts queried for in the different scenarios were easily affordable for most women. Our payment card range was different from the range in other willingness-to-pay studies that have examined medical benefits that are relatively more expensive ($2,000 to >$100,000). 47, 50 Despite the lack of a statistically significant association between willingness to pay and ability to pay in this sample, other findings were consistent with theoretic expectations. Women consistently were willing to pay more for the new Pap test as the performance of the test increased and as their real or perceived risk for developing cervical cancer increased. An initially unexpected finding was that the number of children was a significant driver of willingness to pay. This could indicate that women who had more than 2 children were very riskaverse to dying (and leaving their children motherless) compared with women who had 2 or fewer children. It is possible that this aversion dominated household income as a driver to willingness to pay compared with other analyses in which the participant is less altruistically involved.
When given the choice to publicly fund a new Pap test program for all women or an IVF program for infertile couples, the majority of women chose the new Pap test program, regardless of the number of new births the IVF program could achieve. This indicates that thoughts of mortality are strong drivers of willingness to pay. Another study showed that averting 1 auto death was equivalent to 7.5 babies achieved through IVF. 50 Cropper and Freeman 65 noted that the value of statistical life is approximately 5 times higher in contingent valuation studies than in human capital studies. Future studies might include other trade-off questions to determine how people value liquid-based technologies compared with other health interventions such as acute or chronic care services.
Conclusions
Women are willing to pay $50 to $100 for liquid-based cytology technologies that potentially decrease the risk of dying of cervical cancer. The willingness to pay increases if the perceived benefits also increase. Regression analyses indicated that women with more than 2 children, older women, and women with more education were willing to pay more for the liquid-based cytology technologies. These data indicate that published cost-effectiveness studies generally have used low values for liquid-based cytology technologies.
